Kevin Charles Gorman insider trades

Open-market stock purchases and sales by Kevin Charles Gorman, Director at Neurocrine Biosciences Inc, from SEC Form 4 filings since Jan 12, 2010.

Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +32%.

Recent trades

DateStockTradeValue
Sep 11, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Sep 11, 2026NBIX Neurocrine Biosciences IncSold (not open market)$1.2M
Jun 16, 2026XNCR Xencor IncBought (not open market)—
Jun 16, 2026XNCR Xencor IncBought (not open market)—
Jun 15, 2026XNCR Xencor IncSold$92.7K
May 27, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
May 19, 2026NBIX Neurocrine Biosciences IncSold$37.8M
May 19, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Feb 13, 2026NBIX Neurocrine Biosciences IncSold (not open market)$375K
Feb 13, 2026NBIX Neurocrine Biosciences IncSold (not open market)$360K
Feb 13, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Feb 13, 2026NBIX Neurocrine Biosciences IncSold (not open market)$4.3M
Feb 13, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Feb 13, 2026NBIX Neurocrine Biosciences IncBought (not open market)—
Jan 31, 2026NBIX Neurocrine Biosciences IncSold (not open market)$387K
Jan 31, 2026NBIX Neurocrine Biosciences IncBought (not open market)—

Companies traded

  • NBIX Neurocrine Biosciences Inc: 68 sales, last Sep 11, 2026
  • XNCR Xencor Inc: 1 buy, 3 sales, last Jun 16, 2026

Get free alerts when Kevin Charles Gorman files a new trade →